uniQure N.V. (Nasdaq: QURE) 45.7% HIGHER; Bristol-Myers Squibb (NYSE: BMY) and uniQure N.V. (Nasdaq: QURE) announced an agreement that provides Bristol-Myers Squibb with exclusive access to uniQures gene therapy technology platform for multiple targets in cardiovascular diseases. The collaboration includes uniQures proprietary gene therapy program for congestive heart failure that is intended to restore the hearts ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the
next post